[Molecular genotyping in refractory thyroid cancers in 2021: When, how and why? A review from the TUTHYREF network].

doi:10.1016/j.bulcan.2021.06.009

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

[Molecular genotyping in refractory thyroid cancers in 2021: When, how and why? A review from the TUTHYREF network].

Bulletin du cancer - 1 Nov 2021

de la Fouchardière Christelle, Wassermann Johanna, Calcagno Fabien, Bardet Stéphane, Al Ghuzlan Abir, Borget Isabelle, Borson Chazot Françoise, Do Cao Christine, Buffet Camille, Zerdoud Slimane, Decaussin-Petrucci Myriam, Godbert Yann, Leboulleux Sophie

Abstract excerpt

Refractory thyroid cancers include radio-iodine-refractory cancers, metastatic or locally advanced unresectable medullary and anaplastic thyroid cancers. Their management has been based for several years on the use of multi-target kinase inhibitors, with anti-angiogenic action, with the exception of anaplastic cancers usually treated with chemo- and radiotherapy. The situation has recently evolved due to the...

Read the complete abstract on PubMed